Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
WuXi XDC Cayman, Inc. ( (HK:2268) ) has issued an update.
WuXi XDC Cayman, Inc. has announced revisions to its annual caps for existing connected transactions (CCTs) and plans to renew these agreements for an additional three years, reflecting its strong financial performance and anticipated demand. The company also proposes new CCTs to maximize its manufacturing capacity, subject to regulatory requirements, indicating a strategic move to sustain its growth trajectory and strengthen its market position.
The most recent analyst rating on (HK:2268) stock is a Buy with a HK$73.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
More about WuXi XDC Cayman, Inc.
WuXi XDC Cayman, Inc. is a company operating in the pharmaceutical industry, focusing on the development and manufacturing of antibody-drug conjugates (ADCs). The company is known for its services in contract research, development, and manufacturing (CRDMO), and it benefits from the growing global ADC drug market.
Average Trading Volume: 6,963,270
Technical Sentiment Signal: Buy
Current Market Cap: HK$86.44B
Find detailed analytics on 2268 stock on TipRanks’ Stock Analysis page.